Annals of Oncology Advance Access published online on July 27, 2006
Annals of Oncology, doi:10.1093/annonc/mdl169
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Oncology and Hematology, Clinic Hospital, Valencia, Spain
* To whom correspondence should be addressed. Background: The aim of the study was to determine whether the number of lymph nodes removed at axillary dissection is associated with recurrence and survival in node-negative breast cancer (NNBC) patients. Patients and methods: We retrospectively reviewed the medical records of 1606 women with pathologically node-negative T1-T3 invasive breast cancer. Median follow-up was 61 months (range 2-251). Potential prognostic factors assessed included: number of axillary lymph nodes examined, age, menopausal status, tumor size, histological type, tumor grade, estrogen receptor(ER), progesterone receptor (PR) and HER2. Results: At 5 years, relapse-free survival (RFS) rate was 85% and breast cancer-specific survival (BCSS) rate was 94%. In univariate analysis, factors significantly associated with lower RFS and BCSS were: fewer than six lymph nodes examined (RFS, P = 0.01; BCSS, P = 0.007), tumor size >2 cm, grade III, negative ER or PR. Statistically significant factors for lower RFS and BCSS in multivariate analysis were: fewer than six lymph nodes examined [RFS, hazard ratio (HR) 1.36, P = 0.029; BCSS, HR 1.87, P = 0.005], tumor size >2 cm, tumor grade III and negative PR. Conclusions: Examination of fewer than six lymph nodes is an adverse prognostic factor in NNBC because it could lead to understaging. Six or more nodes need to be examined at axillary dissection to be confident of a node-negative status. This may be useful, in conjunction with other prognostic factors, in the assessment of NNBC patients for adjuvant systemic therapy.
Received May 3, 2006
Revised June 14, 2006
Accepted June 16, 2006
original article
Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor
I. Blancas 1 *, J. L. García-Puche 2, B. Bermejo 1, E. O. Hanrahan 3, C. Monteagudo 4, A. Martínez-Agulló 5, R. Rouzier 6, B. T. Hennessy 3, V. Valero 3, and A. Lluch 1
2 Unit of Oncology, San Cecilio Clinic Hospital, Granada, Spain
3 Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
4 Department of Pathology, Clinic Hospital, Valencia, Spain
5 Department of Surgery, Clinic Hospital, Valencia, Spain
6 Department of Gynecology and Obstetrics, Hôpital Tenon, Tenon, France
I. Blancas, E-mail: isabelblancas{at}hotmail.com
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. O. Hanrahan, A. M. Gonzalez-Angulo, S. H. Giordano, R. Rouzier, K. R. Broglio, G. N. Hortobagyi, and V. Valero Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma J. Clin. Oncol., November 1, 2007; 25(31): 4952 - 4960. [Abstract] [Full Text] [PDF] |
||||
